Published Medical Literature

Cancer-Specific Mortality in Nonmetastatic Renal Cell Carcinoma After Nephrectomy

New Classification System to Track Local Recurrence of Kidney Cancers

Is the p53 Gene More of a Player in Kidney Cancer Than Originally Thought?

Cancer-Specific Mortality Associated With Cryoablation for Renal Cell Carcinoma

Monoclonal Antibody Combination Under Study in Rare Metastatic Kidney Cancer

Mutated ENL Proteins and Pediatric Kidney Cancer

Case Study: Renal Failure Secondary to Pancreatic Metastases From Kidney Cancer

Cell Death Pathways in Targeted Therapy for Renal Cell Carcinoma

Case Studies Focus on Possible Link Between Nivolumab and Pericardial Effusion

New Biomarker in Clear Cell Kidney Cancer?

JAVELIN Solid Tumor Trial: Avelumab Monotherapy for Metastatic Kidney Cancer

Proteogenomics May Improve Diagnosis and Treatment of Kidney Cancer Subtype

Relationship Between Cancer and Mortality Outcomes in Chronic Kidney Disease

Nivolumab Plus Ipilimumab in Advanced Kidney Cancer: CheckMate 214 Update

Do Individuals With Psoriasis Have an Increased Risk for Kidney Cancer?

Toxicity-Based Titration of Axitinib in Metastatic Kidney Cancer

Sunitinib Followed by Second-Line Axitinib in Metastatic Renal Cell Carcinoma

Research Sheds Light on Oncogenes in Clear Cell Renal Cell Carcinoma

Role of Aryl Hydrocarbon Receptor Activation in Kidney Cancer/Disease

Potential Biomarker for Early-Stage Renal Cell Carcinoma

Long Noncoding RNA Signature: Useful Prognostic Tool in Renal Cell Carcinoma?

Stereotactic Ablative Radiotherapy for Oligometastatic Renal Cell Carcinoma

Case Study of ‘Long-Lasting’ Response to Nivolumab in Patient With BRCA1 Mutation

DYSF Expression: Biomarker in Clear Cell Renal Cell Carcinoma?

Update on Systemic Treatments and Sequences in Metastatic Kidney Cancer

Efficiency of Existing Prognostic Models in Renal Cell Carcinoma

Partial Versus Radical Nephrectomy in Elderly Patients With Renal Cancer

Study Finds Limited Activity With Immunotherapy for Brain Metastases From Kidney Cancer

First-Line Treatment With Atezolizumab Plus Bevacizumab Versus Sunitinib in Kidney Cancer

Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer

Collagen Organization in Low- and High-Grade Kidney Tumors

Does Targeted Therapy Improve Survival in Patients With Metastatic Renal Cell Carcinoma?

Immune-Related Adverse Events With Nivolumab: Predicting Outcomes in Kidney Cancer

Monitoring Patients With Kidney Cancer for Cabozantinib-Related Toxicity

Is the Relationship Between Obesity and Outcomes in Kidney Cancer Sex-Specific?

Can Bladder Cancer Be Detected With a Urine Test?

Is Percutaneous Cryoablation a Viable Option for T1b Renal Cell Carcinoma?

Predicting Response to Immunotherapy for Kidney Cancer With FDG-PET/CT

High-Dose IL-2 in Metastatic Kidney Cancer: Outcomes by Risk Groups

Current Status and Future Prospects of Kidney Cancer Treatment

First-Line Combination Therapy in Metastatic Kidney Cancer: Answers and More Questions

Does Tumor Thrombus Affect Outcomes With Cytoreductive Nephrectomy?

KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer

Cabozantinib in Advanced Non–Clear Cell Kidney Cancer

Individualized Sunitinib Therapy for Patients With Metastatic Kidney Cancer

Tisotumab Vedotin Exhibits Antitumor Activity in Bladder Cancer, Among Other Cancers

Adding a Beta-Blocker to Immunotherapy in Kidney Cancers

JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer

Is GRP78 Expression Useful Biomarker for Clear Cell Renal Cell Carcinoma?

Risk of Ovarian Cancer After Radical Cystectomy for Bladder Cancer

Patient-Reported Outcomes in Advanced Renal Cell Carcinoma

Phase I Study of Anti–PD-1 Antibody in Advanced Urologic Cancer

Does Axitinib Improve Outcomes in Favorable-Risk Patients With Metastatic Kidney Cancer?

Renal Function and Cancer-Specific Mortality in Renal Cell Carcinoma

Does Sunitinib Therapy Before Cytoreductive Nephrectomy Improve Outcomes in Metastatic Kidney Cancer?

Prognostic Marker for Non–Muscle-Invasive Bladder Cancer

Neoadjuvant Pembrolizumab Before Surgery in Muscle-Invasive Bladder Carcinoma

Combination of Paclitaxel, Sorafenib, and Radiation in Advanced Kidney Cancer

Combination Immunotherapy in First-Line Treatment of Advanced Kidney Cancer

Muscle-Invasive Bladder Cancer: Two Regimens, Two Successes in Phase II Trial

Using Hub Genes to Predict Outcomes in Clear Cell Kidney Cancer

Kidney Transplantation in Patients With Renal Cell Carcinoma: Defining When and Why

Can Changes in Skeletal Muscle Mass Predict Outcomes in Metastatic Kidney Cancer?

Genomic Alterations and Outcomes in Patients With Renal Cancer Receiving Everolimus

Combining TKIs and Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Utilizing Team-Based Approach to Manage Complex Cases of Kidney Cancer

Choosing Among First-Line Treatments in Advanced Kidney Cancer

Perinephric Fat Deposits and Renal Tumorigenesis

Does Long Noncoding RNA Signature Have Prognostic Value in Kidney Cancer?

Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma

Identifying Renal Transplant Patients at Risk for Squamous Cell Carcinoma by DNA Methylation of T Cells

Metastatic Renal Cell Carcinoma: Sunitinib Alone Versus Nephrectomy

Targeting Metastases in Renal Cell Carcinoma With Stereotactic Radiation

Prevalence of Germline Mutations in Patients With Renal Cell Carcinoma

Distinguishing Subtypes of Kidney Cancer With Histologic Overlap

Lymph Node Dissection and Survival in High-Risk Kidney Cancer

Impact of Biopsychosocial Distress on Outcomes in Metastatic Kidney Cancer

Is There a Long-Term Benefit to TKIs Before Cytroreductive Nephrectomy?

Is Partial Nephrectomy Underused in Younger Patients With cT1 Renal Masses?

Identifying Risk Factors for Recurrence of Nonmetastatic Renal Cell Carcinoma

Relative Dose Intensity in First-Line Sunitinib Therapy for Metastatic Kidney Cancer

Is Neutrophil-Lymphocyte Ratio Predictive of Outcome After Surgery for Metastatic Kidney Cancer?

Potential Biomarker of Response to Sunitinib in Metastatic Kidney Cancer

Outcome Differences Based on Histopathology in Renal Cell Carcinoma

Tumor-Targeted Strategy for Overcoming Chemoresistance in Kidney Cancer

Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer

Early Landmark Events for Patients Diagnosed With Clear Cell Renal Cell Carcinoma

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Timing of Sunitinib Schedule in Patients With Metastatic Renal Cell Carcinoma

Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer

DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer

SABR as an Alternative to Cytoreductive Nephrectomy for Inoperable Kidney Cancer

Predicting Disease Recurrence in Localized Clear Cell Kidney Cancer

Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors

Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance

Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma

Axitinib Plus Pembrolizumab in Advanced Kidney Cancer

METEOR Trial: Quality-of-Life Outcomes in Metastatic Kidney Cancer

Novel Diagnostic Technique for Clear Cell Renal Cell Carcinoma

Cost Sharing and Targeted Therapy Among Older Patients With Kidney Cancer

Crizotinib May Provide Disease Control in Advanced Papillary Renal Cell Carcinoma

Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma

Cabozantinib Versus Everolimus for Bone Metastases From Renal Cell Carcinoma

Familial Clustering of Bladder Cancer Regardless of Smoking History

Managing Cabozantinib-Related Adverse Events in Patients With Renal Cell Carcinoma

Novel Drug for Treatment of Advanced Clear Cell Renal Cell Carcinoma

Is Physical Inactivity an Independent Risk Factor for Renal Cancer?

Stereotactic Ablative Radiation for Renal Tumors

Renal Function With Ablative Techniques for Renal Mass in Solitary Kidney

miR-181a Upregulation and KLF6 Expression in Clear Cell Renal Cell Carcinoma

Recovery of Long-Term Renal Function After Radical Nephrectomy

Therapeutic Implications of Histologic Subtypes in Papillary Renal Cell Carcinoma

Perioperative Blood Transfusion and Prognosis After Surgery for Renal Cancer

Robotic-Assisted Surgery for Radical Nephrectomy: Outcomes and Costs

Potential Molecular Biomarker in Clear Cell Kidney Cancer

Activity and Safety of Tivozanib in Advanced Renal Cell Carcinoma

Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma

Adjuvant Pazopanib After Surgery for Locally Advanced Renal Cell Carcinoma

Multigene Panel Testing in Identifying Hereditary Kidney Cancer

Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer

Sequence of Everolimus and Sunitinib in Metastatic Renal Cell Carcinoma

Can Dynamic Changes During Therapy Predict Survival in Renal Cell Cancer?

Predictive Marker in Nonmetastatic Renal Cell Carcinoma After Nephrectomy

Impact of Margin Status on Survival After Radical Nephrectomy

ALK Inhibitor MK-2206 Versus Everolimus in Refractory Renal Cell Carcinoma

Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer

Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma

Timing of Treatment for Advanced Kidney Cancer

Treatment Outcomes Based on Ethnicity in Metastatic Renal Cell Carcinoma

Combining Nephrectomy and SBRT for Advanced Kidney Cancer

MET Inhibitor Savolitinib in Advanced Papillary Renal Cell Cancer

Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma

Impact of Everolimus-Induced Pneumonitis on Metastatic Renal Cell Carcinoma

Intermittent Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma

Vinflunine Maintenance in Advanced Urothelial Carcinoma

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer

Targeted Therapies for Metastatic Chromophobe Renal Cell Carcinoma

Alternating Treatment Regimens in Clear Cell Renal Cell Cancer

Use of Metformin in Patients With Metastatic Renal Cell Carcinoma

Complete Surgical Metastasectomy in Metastatic Renal Cell Carcinoma

Pazopanib vs Paclitaxel in Advanced Urothelial Carcinoma

Potential Biomarker in Metastatic Renal Cell Carcinoma